The Oncology Institute, Inc. (TOI)

From the record

The Oncology Institute, Inc.'s filings since 2020 show 8 warning events of 5 kinds: a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2024-12-19); a warning not to rely on past financial statements (8-K item 4.02, 2 times, the latest 2021-12-09); an auditor change (8-K item 4.01, the latest 2021-11-18); a material cybersecurity incident (8-K item 1.05, the latest 2026-05-22); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2021-05-18) (its current reports).

From the record

The Oncology Institute, Inc.'s 6 filed years say what it did: revenue went from $188 million in fiscal 2020 to $503 million in fiscal 2025, up 21.8% a year; it rose in 5 of 5 years; it never fell from a peak; net income was positive in 1 of 6 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, The Oncology Institute, Inc.'s shareholders' equity was below zero, so the profit on it is not read. Leverage: it owed about 110 cents per dollar of assets, and net share issuance: its share count grew 23.1% over the year (the filed statements).

From the record

The Oncology Institute, Inc.'s standing among 9 graded names in its industry family: revenue of $503 million in fiscal 2025 ranks in the top 42% by size; a net margin of -12.1% ranks in the bottom 28%; revenue growth of 25.8% a year over the last 3 filed years ranks in the top 28% (its annual reports).

From the record

The Oncology Institute, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Virnich, Daniel (Chief Executive Officer, as filed), filing under that title since 2023-11-16, 3 years (top 37% of its family); most of the 14 officers and directors filing now have filed since the record of its people begins (2021-11-12), a floor of 4.6 years the record cannot see past, so that part is not read; 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (top 30%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

The Oncology Institute, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $34 million against debt of $77 million leaves -26.6% of its assets as net cash, bottom 28% of its family; cash from operations less capital spending is -5.5% of revenue (bottom 28%) (its annual report).

From the record

The Oncology Institute, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 25.8% a year over the last three filed years against 21.8% over all 6, speeding up (top 6% of its family); the newest year grew 27.8% (top 19%); capital spending grew -16.7% a year (top 44%) (its annual reports). The Oncology Institute, Inc. reported 4 product lines in fiscal 2025: Health Care Specialty Pharmacy at $269 million (54%), Fee for Service at $149 million (30%), Capitated Revenue at $80 million (16%), and 1 more; 3 of 4 grew against the year before (its annual report).

From the record

The Oncology Institute, Inc.'s newest year against its own record: revenue of $503 million in fiscal 2025 came in 2.4% above the $491 million its prior three years' pace pointed to (top 42% of its family); net income of $61 million against a prior three-year average of $49 million (bottom 25%); a net margin of -12.1% against -14% before (bottom 25%) (its annual reports).